Hence, the present data validates mutations in genes (e.g. APC, KRAS, NRAS, TP53) known to be involved in (sporadic) CRC development and throughout progression [13, 16, 17, 27] with close reference to the clinico-pathological features. The gene discussed is TP53; the disease is colorectal carcinoma.